2026 Q2 -tulosraportti
UUTTA
1 päivä sitten
‧1 t 2 min
3,75 DKK/osake
Irtoamispäivä 14.8.
3,80%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·9 min sittenIt's seeping in the US. Does anyone know something that others don't know?
·15 min sittenYes, the last couple of hours were just ruined by hopeless meaningless posts from the haters!!! On an otherwise pleasant day on Nordnet with good relevant posts.
- ·18 min sittenFinally a fantastic day for Novo. And pill figures tomorrow. Friday is always a celebration day. Especially regarding the share price.One senses a bit of sarcasm but be careful not to become too smug!! Nemesis tends to strike people who are a bit too arrogant.
·42 min sittenNovo Nordisk may have changed the reporting time for financial reports. But an analyst pointed out just before the reporting day that they must inform the market before the report if the midpoint of the new range is outside the old range. Which it was, and management has probably waited until the last second to have as much clarity as possible on the pill and Medicaid, and thereby potentially increase the upward revision. They may therefore have assessed that it was best to publish everything together. Personally, I believe they should have published the cagrisema diabetes study together with the failed study on Friday, to make room for the upward revision to have its full impact. Many have, however, complained about the former, for which there may have been a very straightforward explanation. “ According to the Swiss major bank UBS, the expected upward revision is not sufficient for Novo Nordisk to issue new financial expectations before the expected time, which is Wednesday at 7:30 AM. “As far as we understand the Danish stock exchange rules, Novo will be obliged to give prior notice if the midpoint of the new range is outside the old range. We do not expect this to happen,” writes Matthew Weston, pharmaceutical analyst at UBS, in a note.”
·50 min sittenHopeless - The only one who thinks things are going well is Mike D. His acquisition strategy is in ruins. Shareholders have lost over 1400 billion on Cagrisema and he maintains its uniqueness. NOVO has nothing left but their arrogance, complacency, and provincial management. Everything is going wrong for them and they still haven't learned to communicate. Lilly would have handled that financial statement presentation completely differently. HopelessLars Rebien and Novo Fonden chose its first successor, and now it has chosen the successor's successor. Believes copies of Rebien. The man with the hats. Both from their own ranks, because imagine if one could find someone from outside with new ideas. Now things are going just as well, and Novo doesn't lack innovation.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
UUTTA
1 päivä sitten
‧1 t 2 min
3,75 DKK/osake
Irtoamispäivä 14.8.
3,80%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 min sittenIt's seeping in the US. Does anyone know something that others don't know?
- ·15 min sittenYes, the last couple of hours were just ruined by hopeless meaningless posts from the haters!!! On an otherwise pleasant day on Nordnet with good relevant posts.
- ·18 min sittenFinally a fantastic day for Novo. And pill figures tomorrow. Friday is always a celebration day. Especially regarding the share price.One senses a bit of sarcasm but be careful not to become too smug!! Nemesis tends to strike people who are a bit too arrogant.
- ·42 min sittenNovo Nordisk may have changed the reporting time for financial reports. But an analyst pointed out just before the reporting day that they must inform the market before the report if the midpoint of the new range is outside the old range. Which it was, and management has probably waited until the last second to have as much clarity as possible on the pill and Medicaid, and thereby potentially increase the upward revision. They may therefore have assessed that it was best to publish everything together. Personally, I believe they should have published the cagrisema diabetes study together with the failed study on Friday, to make room for the upward revision to have its full impact. Many have, however, complained about the former, for which there may have been a very straightforward explanation. “ According to the Swiss major bank UBS, the expected upward revision is not sufficient for Novo Nordisk to issue new financial expectations before the expected time, which is Wednesday at 7:30 AM. “As far as we understand the Danish stock exchange rules, Novo will be obliged to give prior notice if the midpoint of the new range is outside the old range. We do not expect this to happen,” writes Matthew Weston, pharmaceutical analyst at UBS, in a note.”
- ·50 min sittenHopeless - The only one who thinks things are going well is Mike D. His acquisition strategy is in ruins. Shareholders have lost over 1400 billion on Cagrisema and he maintains its uniqueness. NOVO has nothing left but their arrogance, complacency, and provincial management. Everything is going wrong for them and they still haven't learned to communicate. Lilly would have handled that financial statement presentation completely differently. HopelessLars Rebien and Novo Fonden chose its first successor, and now it has chosen the successor's successor. Believes copies of Rebien. The man with the hats. Both from their own ranks, because imagine if one could find someone from outside with new ideas. Now things are going just as well, and Novo doesn't lack innovation.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
2026 Q2 -tulosraportti
UUTTA
1 päivä sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Irtoamispäivä 14.8.
3,80%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 min sittenIt's seeping in the US. Does anyone know something that others don't know?
- ·15 min sittenYes, the last couple of hours were just ruined by hopeless meaningless posts from the haters!!! On an otherwise pleasant day on Nordnet with good relevant posts.
- ·18 min sittenFinally a fantastic day for Novo. And pill figures tomorrow. Friday is always a celebration day. Especially regarding the share price.One senses a bit of sarcasm but be careful not to become too smug!! Nemesis tends to strike people who are a bit too arrogant.
- ·42 min sittenNovo Nordisk may have changed the reporting time for financial reports. But an analyst pointed out just before the reporting day that they must inform the market before the report if the midpoint of the new range is outside the old range. Which it was, and management has probably waited until the last second to have as much clarity as possible on the pill and Medicaid, and thereby potentially increase the upward revision. They may therefore have assessed that it was best to publish everything together. Personally, I believe they should have published the cagrisema diabetes study together with the failed study on Friday, to make room for the upward revision to have its full impact. Many have, however, complained about the former, for which there may have been a very straightforward explanation. “ According to the Swiss major bank UBS, the expected upward revision is not sufficient for Novo Nordisk to issue new financial expectations before the expected time, which is Wednesday at 7:30 AM. “As far as we understand the Danish stock exchange rules, Novo will be obliged to give prior notice if the midpoint of the new range is outside the old range. We do not expect this to happen,” writes Matthew Weston, pharmaceutical analyst at UBS, in a note.”
- ·50 min sittenHopeless - The only one who thinks things are going well is Mike D. His acquisition strategy is in ruins. Shareholders have lost over 1400 billion on Cagrisema and he maintains its uniqueness. NOVO has nothing left but their arrogance, complacency, and provincial management. Everything is going wrong for them and they still haven't learned to communicate. Lilly would have handled that financial statement presentation completely differently. HopelessLars Rebien and Novo Fonden chose its first successor, and now it has chosen the successor's successor. Believes copies of Rebien. The man with the hats. Both from their own ranks, because imagine if one could find someone from outside with new ideas. Now things are going just as well, and Novo doesn't lack innovation.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt